<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215848</url>
  </required_header>
  <id_info>
    <org_study_id>023/2562</org_study_id>
    <nct_id>NCT04215848</nct_id>
  </id_info>
  <brief_title>As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period</brief_title>
  <official_title>Efficacy of As-needed Budesonide/Formoterol Turbuhaler During Stepping Down Period From Step-3 in Adult Patients With Adequately Controlled Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hat Yai Medical Education Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hat Yai Medical Education Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of as-needed Budesonide/formoterol Turbuhaler 160/4.5
      µg/d in the period of step down in well controlled asthmatic patient comparing with standard
      maintenance therapy in step-2 management in asthma guildeline which is low dose inhaled
      corticosteroid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will measure the efficacy of as-needed low dose ICS/ LABA in well controlled
      asthmatic patient comparing with low dose ICS in step down circumstance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First moderate/severe asthma exacerbation rate or loss of asthma controlled</measure>
    <time_frame>Patients will be followed for first moderate/severe asthma exacerbation rate or loss of asthma controlled (an estimated average duration of 48 weeks)</time_frame>
    <description>Duration after the patients who has been randomised to developed asthma exacerbation or loss of asthma control that evaluation by Asthma Controlled Test (ACT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to First moderate/severe asthma exacarbation rate</measure>
    <time_frame>Patients will be followed for first moderate/severe asthma exacerbation rate (an estimated average duration of 48 weeks)</time_frame>
    <description>Duration after randomisation until the patients will develop asthma exacerbation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to First loss of asthma controlled</measure>
    <time_frame>Patients will be followed for loss of asthma controlled (an estimated average duration of 48 weeks)</time_frame>
    <description>Duration after randomisation until the patients will have a loss of asthma control evaluating by Asthma Controlled Test (ACT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The ratio of asthma controlled to total number of participants</measure>
    <time_frame>The ratio of asthma controlled to total number of participants at week 48th.</time_frame>
    <description>The ratio of participants who will be classified for asthma controlled to total number of participants by ACT score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lung function: FEV1%predicted</measure>
    <time_frame>48 weeks.</time_frame>
    <description>Change from baseline in FEV1%predicted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in absoluted eosinophil count</measure>
    <time_frame>48 weeks.</time_frame>
    <description>The change of absoluted eosinophil count after step down medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FENO</measure>
    <time_frame>48 weeks.</time_frame>
    <description>The change of FENO after step down medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean dose of inhaled steroid</measure>
    <time_frame>48 weeks.</time_frame>
    <description>The amount of inhaled steroid dose throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lung function: Peak expiratory flow</measure>
    <time_frame>48 weeks.</time_frame>
    <description>Change from baseline in Peak expiratory flow</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>As-needed Budesonide/Formoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As-needed Budesonide/Formoterol (160/4.5 ug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide (200 ug) twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder</intervention_name>
    <description>After the patients who have all criteria, they will be randomized to take Budesonide/formoterol (160/4.5 μg/d) as need when they have symptoms.</description>
    <arm_group_label>As-needed Budesonide/Formoterol</arm_group_label>
    <other_name>Symbicort Turbuhaler (160/4.5 ug)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 200Mcg Inhalation Powder</intervention_name>
    <description>After the patients who have all criteria, they will be randomized to take Budesonide (200 μg) twice daily</description>
    <arm_group_label>Budesonide</arm_group_label>
    <other_name>Pulmicort Turbuhaler (200 ug)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who have been diagnosed as asthma at least 6 months.

          2. Patients who have well controlled asthma by ACT &gt; 23 and ACQ-7 &lt; 0.75 at least 12
             weeks with using budesonide/formoterol (160/4.5 μg/d) twice daily

          3. Patient who not be taking oral bronchodilator such as montelukast, theophylline,
             doxophylline but accept for taking anti histamine and intranasal steroid.

          4. Patients who able to do spirometry without contraindication.

          5. Patients who have FENO &lt; 25 ppB and absoluted eosinophil count &lt; 300 cell/mm3.

        Exclusion Criteria:

          1. History of using systemic steroid previous 12 week and respiratory infection History
             of pulmonary tuberculosis with residual lung lesion by chest radiograph recent serious
             medical condition such as myocardial infarction, stroke, pneumonia etc.

          2. History smoking less than 10 pack-years or be smoking

          3. History of asthma exacabation previous 12 week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Narongwit Nakwan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hatyai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naongwit Nakwan, M.D.</last_name>
    <phone>66074273100</phone>
    <phone_ext>1223</phone_ext>
    <email>naronak@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Narongwit Nakwan, M.D.</last_name>
    <phone>6674273100</phone>
    <phone_ext>1223</phone_ext>
    <email>naronak@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hatyai Hospital</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narongwit Nakwan, M.D.</last_name>
      <phone>074273100</phone>
      <phone_ext>1223</phone_ext>
      <email>naronak@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hat Yai Medical Education Center</investigator_affiliation>
    <investigator_full_name>Narongwit Nakwan</investigator_full_name>
    <investigator_title>Head of Pulmonology</investigator_title>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

